Which complaint has the most clinical effect on quality of life of thyroid cancer survivors in long term follow up?

Document Type: Original Article

Authors

1 Nuclear Medicine Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Endocrine Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Introduction: Differentiated thyroid cancer (DTC) is the most common endocrine malignancy. This malignancy generally has an excellent prognosis with more than 90% long term survival. Consequently, life quality improvement is the first priority especially in the young DTC survivors. In classic management of a new DTC patient, each therapeutic modality can significantly induce morbidities. In the current study, we investigated the main complaints in DTC patients during the follow up.
Methods: Clinical symptoms of 300 randomly selected DTC patients were collected during their follow up visiting sessions. Related symptoms were any clinical complaint directly due to DTC or its management. The correlation between the most common complaint and age, gender, TNM staging, RAI therapy, external beam radiotherapy and neck surgery was assessed.
Results: Three hundred randomly selected DTC patients (66 male and 234 female) were included. The mean duration of follow up was 5.18±3.48. External radiotherapy of the neck, frequency of radioiodine therapy and repetitive neck operations were associated with more clinical symptoms during long term follow up. The most frequent DTC related complaint was neck discomfort which was reported in 40% of patients. The main background source of patients' complaints was hypothyroidism followed by subclinical hyperthyroidism (p<0.01).

Conclusion: The most common reasons of long term morbidity in DTC patients were related to hypothyroid or subclinical hyperthyroidism. Neck discomfort was the most frequent single complaint with more frequency in patients with repetitive neck operation. The current study could be the first step to discover the unfavorable clinical symptoms of DTC patients.

Keywords

Main Subjects


Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212.

Shafiee S, Sadrizade A, Jafarian A, Zakavi SR, Ayati N. Ectopic papillary thyroid carcinoma in the mediastinum without any tumoral involvement in the thyroid gland. A Case report. Asia Oceania J Nucl Med Biol. 2013;1(1):44-6.

Kayano D, Taki J, Inaki A, Wakabayashi H, Nakamura A, Fukuoka M, Kinuya S. Thyroid hormone replacement one day before 131I therapy in patients with well-differentiated thyroid cancer. Asia Oceania J Nucl Med Biol. 2013;1(1):20-6.

Agate L, Lorusso L, Elisei R. New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. J Endocrinol Invest. 2012;35(6 Suppl):3-9.

Fallahi P, Ferrari SM, Santini F, Corrado A, Materazzi G, Ulisse S, Miccoli P, Antonelli A. Sorafenib and thyroid cancer. BioDrugs. 2013 Dec;27(6):615-28.

Watt T, Groenvold M, Rasmussen AK, Bonnema SJ, Hegedüs L, Bjorner JB, Feldt-Rasmussen U. Quality of life in patients with benign thyroid disorders. A review. Eur J Endocrinol. 2006 Apr;154(4):501-10.

Jaeschke R, Guyatt G, Cook D, Harper S, Gerstein HC. Spectrum of quality of life impairment in hypothyroidism. Qual Life Res. 1994 Oct;3(5):323-7.

Hoogendoorn EH, den Heijer M, van Dijk AP, Hermus AR. Subclinical hyperthyroidism: to treat or not to treat? Postgrad Med J. 2004 Jul;80(945):394-8.

Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, Tennvall J, Bombardieri E; European Association of Nuclear Medicine (EANM). Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1941-59.

Hoftijzer HC, Heemstra KA, Corssmit EP, van der Klaauw AA, Romijn JA, Smit JW. Quality of life in cured patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2008 Jan;93(1):200-3.

Lodemann E, Bockisch A, Görges R. Short-term hypothyroidism in thyroid cancer patients and cognitive-motor performance relevant for driving. Psychoneuroendocrinology. 2012 Oct;37(10):1726-35.

Biondi B, Palmieri EA, Fazio S, Cosco C, Nocera M, Saccà L, Filetti S, Lombardi G, Perticone F. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab. 2000 Dec;85(12):4701-5.

Watt T, Hegedüs L, Rasmussen AK, Groenvold M, Bonnema SJ, Bjorner JB, Feldt-Rasmussen U. Which domains of thyroid-related quality of life are most relevant? Patients and clinicians provide complementary perspectives. Thyroid. 2007 Jul;17(7):647-54.

Gulseren S1, Gulseren L, Hekimsoy Z, Cetinay P, Ozen C, Tokatlioglu B. Depression, anxiety, health-related quality of life, and disability in patients with overt and subclinical thyroid dysfunction. Arch Med Res. 2006 Jan;37(1):133-9.

Lee JI, Kim SH, Tan AH, Kim HK, Jang HW, Hur KY, Kim JH, Kim KW, Chung JH, Kim SW. Decreased health-related quality of life in disease-free survivors of differentiated thyroid cancer in Korea. Health Qual Life Outcomes. 2010 Sep 15;8:101.

Malterling RR, Andersson RE, Falkmer S, Falkmer U, Niléhn E, Järhult J. Differentiated thyroid cancer in a Swedish county--long-term results and quality of life. Acta Oncol. 2010 May;49(4):454-9.

Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC, Ladenson PW. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab. 2006 Mar;91(3):878-84.

Lee J, Yun MJ, Nam KH, Chung WY, Soh EY, Park CS. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid. 2010 Feb;20(2):173-9.

Vethakkan SR, Roberts V, Ward GM. Sudden onset of haemoptysis and hypoxia after recombinant human thyroid-stimulating hormone use in a patient with papillary thyroid carcinoma and pulmonary metastases. Intern Med J. 2009 Dec;39(12):854-5.

Berg G, Andersson T, Sjödell L, Jansson S, Nyström E. Development of severe thyroid-associated ophthalmopathy in a patient with disseminated thyroid cancer treated with recombinant human thyrotropin/radioiodine and retinoic acid. Thyroid. 2005 Dec;15(12):1389-94.

Taïeb D, Jacob T, Zotian E, Mundler O. Lack of efficacy of recombinant human thyrotropin versus thyroid hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid carcinoma lung metastases. Thyroid. 2004 Jun;14(6):465-7.

Vargas GE, UY H, Bazan C, Guise TA, Bruder JM. Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain. J Clin Endocrinol Metab. 1999 Nov;84(11):3867-71.

Lombardi CP, Raffaelli M, De Crea C, D'Alatri L, Maccora D, Marchese MR, Paludetti G, Bellantone R. Long-term outcome of functional post-thyroidectomy voice and swallowing symptoms. Surgery. 2009 Dec;146(6):1174-81.

Stojadinovic A, Shaha AR, Orlikoff RF, Nissan A, Kornak MF, Singh B, Boyle JO, Shah JP, Brennan MF, Kraus DH. Prospective functional voice assessment in patients undergoing thyroid surgery. Ann Surg. 2002 Dec;236(6):823-32.

Ryu J, Ryu YM, Jung YS, Kim SJ, Lee YJ, Lee EK, Kim SK, Kim TS, Kim TH, Lee CY, Park SY, Chung KW. Extent of thyroidectomy affects vocal and throat functions: a prospective observational study of lobectomy versus total thyroidectomy. Surgery. 2013 Sep;154(3):611-20.

Safioleas M1, Stamatakos M, Rompoti N, Mouzopoulos G, Iannescu R, Salichou V, Skandalakis P. Complications of thyroid surgery. Chirurgia (Bucur). 2006 Nov-Dec;101(6):571-81.

Röher HD, Goretzki PE, Hellmann P, Witte J. Complications in thyroid surgery. Incidence and therapy. Chirurg. 1999 Sep;70(9):999-1010.

Sciumè C, Geraci G, Pisello F, Facella T, Li Volsi F, Licata A, Modica G. Complications in thyroid surgery: symptomatic post-operative hypoparathyroidism incidence, surgical technique, and treatment. Ann Ital Chir. 2006 Mar-Apr;77(2):115-22.

Fard-Esfahani A, Emami-Ardekani A, Fallahi B, Fard-Esfahani P, Beiki D, Hassanzadeh-Rad A, Eftekhari M.Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nucl Med Commun. 2014 Aug;35(8):808-17.

Almeida JP, Vartanian JG, Kowalski LP. Clinical predictors of quality of life in patients with initial differentiated thyroid cancers. Arch Otolaryngol Head Neck Surg. 2009 Apr;135(4):342-6.